RESHAPE LIFESCIENCES INC (RSLS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:RSLS • US76090R3093

3.92 USD
+0.72 (+22.5%)
At close: Aug 14, 2025
3.22 USD
-0.7 (-17.86%)
After Hours: 8/14/2025, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall RSLS gets a fundamental rating of 2 out of 10. We evaluated RSLS against 186 industry peers in the Health Care Equipment & Supplies industry. RSLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RSLS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • RSLS had negative earnings in the past year.
  • In the past year RSLS has reported a negative cash flow from operations.
  • RSLS had negative earnings in each of the past 5 years.
  • In the past 5 years RSLS always reported negative operating cash flow.
RSLS Yearly Net Income VS EBIT VS OCF VS FCFRSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -53.42%, RSLS is not doing good in the industry: 66.84% of the companies in the same industry are doing better.
  • With a Return On Equity value of -281.54%, RSLS is not doing good in the industry: 77.01% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -53.42%
ROE -281.54%
ROIC N/A
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RSLS Yearly ROA, ROE, ROICRSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

  • With a decent Gross Margin value of 63.74%, RSLS is doing good in the industry, outperforming 65.24% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RSLS has grown nicely.
  • RSLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
RSLS Yearly Profit, Operating, Gross MarginsRSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • RSLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RSLS has been increased compared to 1 year ago.
  • RSLS has more shares outstanding than it did 5 years ago.
  • RSLS has a worse debt/assets ratio than last year.
RSLS Yearly Shares OutstandingRSLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5K 10K 15K 20K 25K
RSLS Yearly Total Debt VS Total AssetsRSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • RSLS has an Altman-Z score of -130.89. This is a bad value and indicates that RSLS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of RSLS (-130.89) is worse than 96.26% of its industry peers.
  • There is no outstanding debt for RSLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -130.89
ROIC/WACCN/A
WACC8.88%
RSLS Yearly LT Debt VS Equity VS FCFRSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • RSLS has a Current Ratio of 1.53. This is a normal value and indicates that RSLS is financially healthy and should not expect problems in meeting its short term obligations.
  • RSLS's Current ratio of 1.53 is on the low side compared to the rest of the industry. RSLS is outperformed by 73.80% of its industry peers.
  • RSLS has a Quick Ratio of 1.53. This is a bad value and indicates that RSLS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • RSLS has a worse Quick ratio (0.91) than 82.35% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 0.91
RSLS Yearly Current Assets VS Current LiabilitesRSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • RSLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.64%, which is quite impressive.
  • RSLS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.93%.
  • Measured over the past years, RSLS shows a quite strong growth in Revenue. The Revenue has been growing by 19.54% on average per year.
EPS 1Y (TTM)93.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114%
Revenue 1Y (TTM)-13.93%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-42.75%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year20%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RSLS Yearly Revenue VS EstimatesRSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M
RSLS Yearly EPS VS EstimatesRSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RSLS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RSLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RSLS Price Earnings VS Forward Price EarningsRSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RSLS Per share dataRSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RSLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

RESHAPE LIFESCIENCES INC

NASDAQ:RSLS (8/14/2025, 8:00:01 PM)

After market: 3.22 -0.7 (-17.86%)

3.92

+0.72 (+22.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12
Earnings (Next)11-12
Inst Owners0.73%
Inst Owner Change0%
Ins Owners0.06%
Ins Owner Change0%
Market Cap81.26M
Revenue(TTM)7.17M
Net Income(TTM)-3.46M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.33
P/FCF N/A
P/OCF N/A
P/B 66.07
P/tB 66.07
EV/EBITDA N/A
EPS(TTM)-212.11
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0.35
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -53.42%
ROE -281.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.74%
FCFM N/A
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
F-Score3
Asset Turnover1.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 0.91
Altman-Z -130.89
F-Score3
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)11.32%
Cap/Depr(5y)20.35%
Cap/Sales(3y)0.55%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114%
EPS Next Y20%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-13.93%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-42.75%
Revenue Next Year20%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.15%
OCF growth 3YN/A
OCF growth 5YN/A

RESHAPE LIFESCIENCES INC / RSLS FAQ

What is the fundamental rating for RSLS stock?

ChartMill assigns a fundamental rating of 2 / 10 to RSLS.


What is the valuation status of RESHAPE LIFESCIENCES INC (RSLS) stock?

ChartMill assigns a valuation rating of 0 / 10 to RESHAPE LIFESCIENCES INC (RSLS). This can be considered as Overvalued.


What is the profitability of RSLS stock?

RESHAPE LIFESCIENCES INC (RSLS) has a profitability rating of 1 / 10.


What is the expected EPS growth for RESHAPE LIFESCIENCES INC (RSLS) stock?

The Earnings per Share (EPS) of RESHAPE LIFESCIENCES INC (RSLS) is expected to grow by 20% in the next year.